Latest Trials

Total 4060 results

AstraZeneca

Completed

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY) (MELODY)

Respiratory Syncytial Virus Infections

United States, Finland, Spain, Belgium, France, Korea, Republic of, Turkey, Austria, New Zealand, South Africa, Australia, Germany, Bulgaria, United Kingdom, Ukraine, Argentina, Czechia, Panama, Estonia, Lithuania, Poland, Japan, Co... and more
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (CheckMate 9DX)

Hepatocellular Carcinoma | Liver Cancer

United States, Canada, Germany, France, Russian Federation, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Hong Kong, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Puerto Rico, Romania, Sing... and more
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

Melanoma

United States, Italy, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Mexico, Norway, Romania, Spain, Sweden, Switzerland, United Kingdom
Theravance Biopharma

Terminated

Efficacy and Safety of TD-1473 in Crohn's Disease (DIONE)

Crohn's Disease

United States, Bulgaria, France, Georgia, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Portugal, Romania, Serbia, South Africa, Spain, Ukraine, Australia, Austria, Croatia, New Zealand, Russian Federation, United...
AbbVie

Completed

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs (SELECT-BEYOND)

Rheumatoid Arthritis

United States, Australia, Austria, Belgium, Canada, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Korea, Republic of, Latvia, New Zealand, Poland, Portugal, Puerto Rico, Russian Federation, Slovakia, ... and more
Pfizer

Completed

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Metastatic or Unresectable Cutaneous Melanoma

United States, Spain, Canada, Italy, United Kingdom, Germany, Korea, Republic of, France, Australia, Czechia, Russian Federation, Turkey, Israel, Netherlands, Greece, Hungary, Japan, Portugal, Argentina, Austria, Belgium, Brazil, Po... and more
Biogen

Completed

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)

Relapsing-Remitting Multiple Sclerosis

United States, France, Germany, Spain, Belgium, Czechia, Switzerland, United Kingdom, Austria, New Zealand, Australia, South Africa, Ukraine, Italy, Slovakia, Greece, Poland, Israel, Netherlands, Bulgaria, Serbia, India, Romania, Estonia and more
Gilead Sciences

Terminated

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (STELLAR-4)

Nonalcoholic Steatohepatitis

United States, Spain, Hong Kong, Canada, Belgium, Australia, Taiwan, India, Japan, Korea, Republic of, Singapore, United Kingdom, Israel, Puerto Rico, France, New Zealand, Germany, Austria, Italy, Mexico, Poland, Switzerland
Amgen

Completed

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)

Multiple Myeloma

Korea, Republic of, China, Spain, Taiwan, United States, Netherlands, Australia, Singapore, New Zealand, United Kingdom, Israel, France, Japan, Italy, Czechia, Belgium, Argentina, Austria, Bulgaria, Canada, Germany, Greece, Hungary, M... and more
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM)

Castration-Resistant Prostate Cancer

United States, Canada, France, Spain, United Kingdom, Australia, Poland, Germany, Austria, Belgium, Netherlands, Italy, Chile, South Africa, Argentina
Human Genome Sciences Inc., a GSK Company
GlaxoSmithKline

Completed

A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) (BLISS-SC)

Systemic Lupus Erythematosus

United States, Spain, Ukraine, Taiwan, Bulgaria, Poland, United Kingdom, Belgium, Philippines, Sweden, Thailand, Germany, Italy, Japan, Portugal, Malaysia, Romania, Argentina, Brazil, Colombia, Czechia, France, Austria, Denmark, Mexico, Russian... and more
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

Alzheimer's Disease

United States, Germany, Canada, Austria
Abbott

Completed

Post-marketing Observational Study in Subjects With Rheumatoid Arthritis (ReAlise)

Rheumatoid Arthritis

Australia, Austria, Belgium, France, Germany, Greece, Italy, Netherlands, Portugal, Spain, United Kingdom
AstraZeneca

Recruiting

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA)

Viral Lung Infection and Acute Respiratory Failure

United States, China, Australia, Czechia, Denmark, Hungary, Israel, Spain, United Kingdom, Canada, Germany, Italy, Argentina, Bulgaria, India, Turkey, Vietnam, Japan, France, Egypt, Malaysia, Taiwan, Thailand, Brazil, Greece, Belgium, Hong... and more
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (Dapa-CKD)

Chronic Kidney Disease

United States, Canada, Spain, United Kingdom, Denmark, Germany, Korea, Republic of, Brazil, Hungary, Mexico, Peru, Philippines, Vietnam, China, Japan, Argentina, Ukraine, Poland, Russian Federation, India, Sweden
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

Influenza A

United States, France, Korea, Republic of, Taiwan, China, India, Argentina, Israel, Thailand, Vietnam, Hungary, Germany, South Africa, Spain, Turkey, Belgium, Brazil, Canada, Mexico, New Zealand, Bulgaria, Peru, Malaysia, Italy, Estonia, ... and more
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314)

Chronic Lymphocytic Leukemia | Leukemia, B-cell | Small Lymphocytic Lymphoma | Leukemia, Lymphocytic

United States, Spain, Canada, Korea, Republic of, Taiwan, Australia, Japan, New Zealand, Italy, Czechia, China, Hungary, Israel, Belgium, France, Poland, Germany, Argentina, United Kingdom, Brazil, Turkey, Chile, Austria
United Therapeutics

Recruiting

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Cardiovascular Diseases | Vascular Diseases | Lung Diseases | Hypertension | Connective Tissue Diseases | Pulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Hypertension, Pulmonary | Pulmonary Hypertension | PAH | Respiratory Tract Disease

United States, Australia, Austria, Italy, Taiwan, Spain, Korea, Republic of, Canada, United Kingdom, Singapore, Argentina, Germany, France, Belgium, Mexico, Brazil, Hungary, Bulgaria, Chile, Czechia, Denmark, Greece, Israel, Netherlands, Pola... and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany; GORTEC (Head and Neck Oncology and Radiotherapy...

Active, not recruiting

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

Squamous Cell Carcinoma of the Head and Neck

United States, Spain, Korea, Republic of, Taiwan, China, Argentina, France, Japan, Israel, United Kingdom, Belgium, Germany, Portugal, Greece, Italy, Georgia, Australia, Czechia, Brazil, Canada, Austria, Russian Federation, Switzerland and more
Merck Sharp & Dohme LLC
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Active, not recruiting

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

Uterine Cervical Neoplasms

Canada, United States, Australia, Austria, Belgium, Brazil, Chile, China, Colombia, Czechia, France, Germany, Greece, Guatemala, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Norway, Peru, Russian Federation, Spain, Sweden, ... and more
Madrigal Pharmaceuticals, Inc.

Active, not recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH)

NASH - Nonalcoholic Steatohepatitis

United States, Spain, Australia, United Kingdom, Canada, Israel, Belgium, Italy, France, Puerto Rico, Switzerland, Germany, Austria, Poland, Mexico, Hungary
Sumitomo Pharma America, Inc.

Completed

A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P)

Carcinoma, Pancreatic Ductal

United States, France, Netherlands, Spain, Taiwan, China, Belgium, Korea, Republic of, Austria, Singapore, Japan, Italy, Germany, Portugal, Poland, Czechia, Australia, Canada, Russian Federation, Ukraine
Intercept Pharmaceuticals

Terminated

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT)

Liver Cirrhosis, Biliary

United States, Spain, Korea, Republic of, Australia, Finland, Israel, Lithuania, United Kingdom, Belgium, Netherlands, Estonia, Brazil, Italy, Serbia, Sweden, Argentina, Austria, Canada, Chile, Denmark, France, Germany, Hong Kong, Hun... and more
Novartis Pharmaceuticals

Completed

Dose Finding Study for QAW039 in Asthma

Asthma

United States, Colombia, India, Romania, South Africa, Italy, Hungary, France, Bulgaria, Turkey, Greece, Guatemala, Japan, Argentina, Austria, Mexico, Netherlands, Peru, Poland, Russian Federation, United Kingdom, Canada
Cubist Pharmaceuticals LLC
GlaxoSmithKline

Completed

Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Constipation | Bowel Dysfunction

United States, Taiwan, Australia, Canada, Hungary, Spain, Finland, United Kingdom, Hong Kong, Sweden, Austria, Denmark, Poland, Netherlands, New Zealand, Ireland, Switzerland
GlaxoSmithKline

Completed

Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting

Nausea | Vomiting | Nausea and Vomiting, Chemotherapy-Induced

United States, Germany, Bulgaria, Hungary, Philippines, Russian Federation, Taiwan, Korea, Republic of, Belgium, Denmark, Hong Kong, Slovakia, South Africa, Spain, Ireland, Latvia, Thailand, Italy, United Kingdom, Argentina, Aus... and more
Bayer

Recruiting

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Biochemically Recurrent Prostate Cancer

Austria, Spain, United States, Australia, Brazil, France, Germany, Taiwan, Denmark, China, Netherlands, Portugal, Japan, Canada, Finland, Italy, Hungary, United Kingdom, Poland, Israel, New Zealand, Sweden, Belgium, Czechia
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2)

Relapsed or Refractory Multiple Myeloma

United States, Austria, Denmark, Canada, Australia, China, Spain, Germany, United Kingdom, Hungary, Taiwan, Israel, Japan, India, Norway, Brazil, Italy, Greece, Korea, Republic of, Colombia, Singapore, Netherlands, Argentina, Hong Kong, Romani... and more
Pfizer

Recruiting

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

Multiple Myeloma

Japan, Belgium, United States, Netherlands, Australia, Austria, Taiwan, China, Spain, Canada, Israel, Germany, Italy, Czechia, Korea, Republic of, Norway, Finland, France, Sweden, Brazil, Greece, Turkey, United Kingdom, Hungary, Poland, I...
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

Metastatic Non Small Cell Lung Cancer

United States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more
Celgene

Recruiting

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States, Belgium, Australia, Canada, Italy, Austria, Germany, Israel, Japan, Poland, Portugal, Spain, United Kingdom, Argentina, Switzerland
Seagen Inc.

Recruiting

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

HER2-positive Breast Cancer

United States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Carcinoma, Non-squamous Non-small-cell Lung

Poland, Korea, Republic of, Ukraine, United States, Argentina, Australia, Austria, Canada, France, Japan, New Zealand, Romania, Russian Federation, Taiwan, Turkey, United Kingdom, Brazil, Colombia, Germany, Spain
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
EMD Serono Research & Development Institute, Inc.

Terminated

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Relapsing Multiple Sclerosis

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Colombia, Croatia, Czechia, Estonia, Finland, France, Georgia, Germany, Hong Kong, Hungary, India, Israel, Italy, Korea, Republic of, M... and more
AbbVie

Enrolling by invitation

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (AD Up)

Atopic Dermatitis

United States, Australia, Austria, Belgium, Canada, China, Czechia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Puerto Rico, Slovakia, Spain, Sweden, United Kingdom
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Breast Cancer

China, United States, Spain, Hungary, Israel, Korea, Republic of, Taiwan, Belgium, Austria, Russian Federation, Switzerland, Portugal, France, Canada, Italy, United Kingdom, Greece, Japan, Germany, Sweden
AbbVie

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA)

Giant Cell Arteritis (GCA)

United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Romania, Russian Federation, Spain, Sweden, Switzerland, United...
Eli Lilly and Company

Completed

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Non-Small Cell Lung Cancer

United States, Germany, Israel, Italy, Mexico, France, Poland, Romania, Spain, Taiwan, United Kingdom, Hungary, Austria, Argentina, Korea, Republic of, Greece, Turkey, India, Netherlands, Russian Federation, Canada, Norway, Sweden, Br... and more
Gilead Sciences

Completed

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI) (RIVER-PCI)

Coronary Artery Disease | Angina Pectoris

United States, Spain, Israel, Canada, Belgium, Italy, Germany, France, Sweden, Russian Federation, United Kingdom, Austria, Czech Republic, Poland, Netherlands
GlaxoSmithKline

Completed

Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir Hypersensitivity

HIV Infection

Spain, Germany, France, Israel, Belgium, United Kingdom, Netherlands, Austria, Ireland, Slovenia, Russian Federation, Italy, Australia, Portugal, Romania, Poland, Switzerland, Norway, Latvia
Hoffmann-La Roche

Completed

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (SafeHER)

Breast Neoplasms

Hungary, Italy, United Kingdom, Canada, Czechia, Bulgaria, Croatia, Dominican Republic, France, Germany, Greece, Guatemala, Hong Kong, Indonesia, Ireland, Korea, Republic of, Netherlands, Panama, Peru, Poland, Portugal, Slovakia, Spain and more
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

Relapsing Multiple Sclerosis

China, Spain, Switzerland, Taiwan, United States, Italy, Austria, Belgium, Saudi Arabia, United Arab Emirates, Latvia, Poland, Argentina, India, Croatia, Bulgaria, Malaysia, Slovakia, Israel, Lebanon, Guatemala, Netherlands, Colombia, Chil... and more
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

High-risk Non-muscle Invasive Bladder Cancer

Canada, Belgium, United States, Australia, Austria, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, China, Brazil, Colombia, ... and more
Astellas Pharma Global Development, Inc.
Pfizer

Recruiting

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Prostate Cancer

United States, Korea, Republic of, Japan, Belgium, Spain, Argentina, Australia, Canada, Chile, Czechia, Denmark, Finland, France, Georgia, Germany, Israel, Italy, Moldova, Republic of, New Zealand, Poland, Russian Federation, Slov... and more
Pfizer
Merck Sharp & Dohme LLC

Active, not recruiting

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Melanoma

France, United States, Hungary, Italy, Spain, Czechia, Belgium, Germany, New Zealand, Canada, Austria, Israel, Poland, Russian Federation, Turkey, Switzerland, South Africa, Slovakia, United Kingdom, Ukraine, Brazil, Argentina, Bulg... and more
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

Carcinoma, Squamous Cell, Non-small-cell Lung

Poland, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Japan, Mexico, New Zealand, Romania, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) (LEAP-001)

Endometrial Neoplasms

Brazil, United States, Argentina, Australia, Austria, Belgium, Canada, China, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

Non-Small Cell Lung Cancer

Poland, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Norway, Romania, Russian Federation, Spain, Switzerland, Taiwan, Turkey, Ukr... and more
Incyte Corporation

Completed

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Graft-versus-host Disease (GVHD)

Belgium, Italy, Spain, Saudi Arabia, Turkey, United Kingdom, Germany, Greece, Canada, Austria, France, Israel, Netherlands, Sweden, Switzerland, Korea, Republic of, Bulgaria, Japan, Norway, Czechia, Russian Federation, Jordan, Hungary, Ind... and more
Gilead Sciences

Approved for marketing

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

SARS-CoV2 Infection

United States, Israel, Belgium, Spain, Australia, Denmark, Italy, Germany, France, Portugal, United Kingdom, Poland, Switzerland, Canada, Austria, Cyprus, Czechia, Estonia, Greece, Hungary, Iceland, Ireland, Lithuania, Netherlands, Romania and more

Latest Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations